47 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
13 Feb 24
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
7:34pm
and patents expenses was due to the Company having completed the INM-755 Phase 2 clinical trial, offset by an increase in external contractor fees and personnel … fees, accounting and legal fees in the InMed segment offset by higher accounting and legal fees, and marketing expenses in the BayMedica segment
8-K
EX-99.1
n7tb8tcoi8j7
29 Sep 23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
x32wb99jnlh 9lwo
16 May 23
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
1:47pm
8-K
EX-99.1
7dw1e0qq r8kvymul9j
14 Nov 22
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
5:44pm
424B5
iipeui7x 3vc
3 Jun 22
Prospectus supplement for primary offering
9:45pm
8-K
EX-99.1
b3lpa3ny
18 May 22
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
1:34pm
424B3
04hsvj d3serr1bno
25 Apr 22
Prospectus supplement
5:02pm
424B3
sn86gya9r54tllhb
7 Apr 22
Prospectus supplement
4:46pm